Skip to main content
. Author manuscript; available in PMC: 2019 Mar 27.
Published in final edited form as: Breast Cancer Res Treat. 2017 Sep 6;167(1):195–203. doi: 10.1007/s10549-017-4432-0

Table 1.

The percent of cases requiring second (2nd) and third (3rd) reviews, misclassification rates (MCR), false positive (FP), and false negative (FN) proportions by pathology interpretation strategy and expert consensus diagnosis*

Pathology interpretation strategy Proliferative/non-prolif.
Reference standard expert consensus diagnosis
Atypia
DCIS
Invasive
Reviews 2nd, 3rd MCR (FN, FP) Reviews 2nd, 3rd MCR (FN, FP) Reviews 2nd, 3rd MCR (FN, FP) Reviews 2nd, 3rd MCR (FN, FP)
No second opinion 0.0, 0.0 5.8 (0,5.8) 0.0, 0.0 52.2 (34.7,17.4) 0.0, 0.0 15.9 (13.3,2.6) 0.0, 0.0 3.9 (3.9,0)
Second opinion based on initial diagnosis
 2nd if invasive 1.0, 0.8 5.4 (0,5.4) 0.4, 0.3 51.9 (34.4,17.5) 2.6, 2.4 13.6 (13.2,0.4) 96.1, 1.9 4.7 (4.7,0)
 2nd if invasive or DCIS 3.2, 2.9 4.7 (0,4.7) 17.4, 13.1 43.7 (35.9,7.9) 86.7, 12.2 15.8 (15.2,0.6) 99.6, 3.3 3.9 (3.9,0)
 2nd if invasive, DCIS or atypia 12.9, 10.4 2.1 (0,2.1) 65.3, 36.5 51.9 (41.8,10) 93.7, 17.8 12.1 (11.4,0.6) 99.6, 3.3 3.9 (3.9,0)
Second opinion based on pathologist desire or policy
 2nd if desired 26.7,10.1 3.3 (0,3.3) 55.9, 31.3 47.7 (33.7,14) 30.5, 11.2 11.4 (9.9,1.5) 15.5, 1.5 3.6 (3.6,0)
 2nd if considered borderline 19, 7.5 4.0 (0, 4.0) 45.3, 25.6 48.9 (34.6,14.2) 21.4, 9.3 11.5 (9.9,1.5) 3.5,0.8 3.8 (3.8,0)
 2nd if required by policy 33.8, 7.6 4.7 (0,4.7) 40.6, 23 47.1 (33.9,13.2) 55.3, 10.0 13.7 (12.1,1.6) 59.9, 2.1 4.0 (4.0,0)
 2nd if desired or required 54, 14.9 2.9 (0,2.9) 80.4, 45.3 44.3 (32.8,11.4) 75.5, 18.0 10.3 (9.5,0.9) 69.8, 3 3.7 (3.7,0)
 Second opinion for all 100, 19.7 2.9 (0,2.9) 100, 55.9 40.9 (29.9,11.1) 100, 21.6 9.9 (9.3,0.6) 100, 3.7 3.5 (3.5,0)
*

Second opinion strategies require resolution by the third reviewer if the first two disagree